Related Experiment Video
Updated: Aug 12, 2026
08:27
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
Audio‒Visual Gamma Stimulation for Alzheimer's Disease: Current Evidence and Future Directions
Fateme Maghsoudlou1, Ali Esteki1
1Department of Biomedical Engineering, Shahid Beheshti University of Medical Sciences, Arabi Avenue, Daneshjoo Boulevard, Velenjak, Tehran 1985717443, Iran.
Current Alzheimer Research
|August 11, 2026
Summary
Forty-hertz gamma stimulation shows promise as a safe, non-invasive therapy for Alzheimer's Disease (AD), potentially improving cognitive function and neural activity. Further large-scale studies are needed to confirm its long-term efficacy and clinical utility.
Area of Science:
- Neuroscience
- Neurology
- Biomedical Engineering
Background:
- Alzheimer's Disease (AD) involves cognitive decline and disrupted neural oscillations.
- Non-invasive 40 Hz gamma stimulation is an emerging therapeutic approach for AD.
Purpose of the Study:
- To review the safety, tolerability, and clinical outcomes of 40 Hz gamma stimulation in Alzheimer's Disease.
- To evaluate evidence from the past decade regarding this intervention.
Main Methods:
- Literature search of PubMed, Web of Science, Google Scholar, and ClinicalTrials.gov for studies within the last ten years.
- Inclusion of registered and ongoing studies from ClinicalTrials.gov.
- Extraction of data on stimulation parameters, safety, tolerability, functional connectivity, brain atrophy, cognition, and sleep.
Main Results:
- Thirty studies identified: 8 sensory, 12 tACS, 10 ongoing trials.
- Completed studies (n=20) indicate 40 Hz gamma stimulation is safe and well-tolerated.
- Evidence suggests potential benefits for functional connectivity, reduced brain atrophy, cognitive function, and sleep.
Conclusions:
- 40 Hz gamma stimulation is a feasible, well-tolerated intervention with potential for Alzheimer's Disease treatment.
- Current evidence is limited by small sample sizes, methodological heterogeneity, and short follow-up.
- Large-scale, randomized, controlled trials are necessary to establish efficacy and clinical utility.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...